Gross Profit Comparison: AbbVie Inc. and Amneal Pharmaceuticals, Inc. Trends

AbbVie vs. Amneal: A Decade of Profit Trends

__timestampAbbVie Inc.Amneal Pharmaceuticals, Inc.
Wednesday, January 1, 201415534000000449634000
Thursday, January 1, 201518359000000499226000
Friday, January 1, 201619805000000597455000
Sunday, January 1, 201721176000000526178000
Monday, January 1, 201825035000000716403000
Tuesday, January 1, 201925827000000352997000
Wednesday, January 1, 202030417000000628393000
Friday, January 1, 202138751000000768973000
Saturday, January 1, 202240640000000784708000
Sunday, January 1, 202333903000000820565000
Monday, January 1, 202439430000000
Loading chart...

Unlocking the unknown

A Tale of Two Pharmaceutical Giants: AbbVie Inc. vs. Amneal Pharmaceuticals, Inc.

In the ever-evolving pharmaceutical industry, the financial health of companies is a key indicator of their market position and potential for innovation. Over the past decade, AbbVie Inc. has consistently demonstrated robust growth in gross profit, with a remarkable increase of approximately 118% from 2014 to 2023. This growth trajectory underscores AbbVie's strategic prowess and its ability to capitalize on market opportunities.

In contrast, Amneal Pharmaceuticals, Inc. has shown a more modest growth pattern, with gross profits increasing by around 82% over the same period. While Amneal's growth is commendable, it highlights the competitive challenges smaller pharmaceutical companies face in scaling their operations.

This comparison not only reflects the dynamic nature of the pharmaceutical sector but also emphasizes the importance of strategic planning and market adaptation in achieving financial success.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025